Article Information
History
- September 22, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- John D. Rioux, PhD1,2,*,
- Gabrielle Boucher, MSc1,
- Anik Forest, MSc1,
- Bertrand Bouchard, MSc1,
- Lise Coderre, PhD3,
- Caroline Daneault, MSc1,
- Isabelle Robillard Frayne, MSc1,
- Julie Thompson Legault, MSc1,
- iGenoMed Consortium,
- Alain Bitton, MD4,
- Ashwin Ananthakrishnan, MD5,6,
- Sylvie Lesage, PhD3,7,
- Ramnik J. Xavier, MD5,6 and
- Christine Des Rosiers, PhD1,8
- 1Montreal Heart Institute Research Center, Montreal, Quebec, Canada
- 2Université de Montréal, Faculty of Medicine, Montreal, Quebec, Canada
- 3Maisonneuve-Rosemont Hospital Research Center, Montréal, Québec, Canada
- 4McGill University Health Centre, Division of Gastroenterology, Montreal, Quebec, Canada
- 5Division of Gastroenterology, Massachusetts General Hospital, Boston, MA, USA
- 6Harvard Medical School, Boston, MA, USA
- 7Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montréal, Québec, Canada
- 8Département de Nutrition, Université de Montréal, Montréal, Québec, Canada
- ↵*Address correspondence to
: John D. Rioux, PhD, Montreal Heart Institute, Research Center, 5000 Bélanger, Montréal, Québec, H1T 1C8, Canada. TEL: (514) 376-3330 x3741 EMAIL: (john.david.rioux{at}umontreal.ca)
Posted September 22, 2024.
A pilot study to identify blood-based markers associated with response to treatment with Vedolizumab in patients with Inflammatory Bowel Disease
